Login to Your Account



Clinic Roundup


Tuesday, September 17, 2013
• Pluristem Therapeutics Inc., of Haifa, Israel, said the FDA lifted the clinical hold placed June 4 on the company’s Phase II intermittent claudication study, stating that the company had addressed all the clinical hold issues and may proceed with the trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription